Zulitor Tablets 4mg

 

Category: Pharmaceutical

Exhibitor: ORIENT PHARMA CO., LTD.

Booth No: L228

 

Characteristic

 

Zulitor (pitavastatin 4mg) demonstrates strong efficacy and safety across both pre-marketing trials and post-marketing real-world studies, making it a highly suitable option for patients at elevated cardiovascular risk. According to Asian clinical studies have shown that high-dose pitavastatin (4mg) reduces cardiovascular event risk by 19% and lowers LDL-C levels by up to 47%.

Importantly, Zulitor has minimal impact on glycemic control in both diabetic and non-diabetic patients and is metabolized via a non-CYP450 pathway, reducing the risk of drug-drug interactions. Post-marketing safety data from Taiwan’s National Health Insurance Research Database further confirm the favorable safety profile of pitavastatin, showing a lower incidence of hepatotoxicity, rhabdomyolysis, and new-onset diabetes compared to other statins. These findings enhance the clinical confidence in Zulitor as an optimal lipid-lowering therapy, particularly for patients with complex comorbidities.

 

Other Products

 

• 

  Methydur Sustained Release Capsules

• 

  Tonvasca Capsules 2/10 mg

• 

  Jakop (Tofacitinib) Extended Release Tablet

• 

  Vancover Capsules 125 mg

• 

  Rivastigmine Patch 9.5mg/24hrs

• 

  Trokendi XR extended release capsules 25mg, 50mg, 100mg

 

 

 

Back